Nottingham-based Contract Research Organisation (CRO) XenoGesis has opened a state-of-the-art Bioanalysis suite at BioCity following significant investment in two mass spectrometers, further expanding its bioanalysis capabilities.
As part of the continuing commitment to provide the best possible service to its global client base by investing in the latest cutting edge technology, XenoGesis recently made a significant upgrade to their laboratory capabilities. They approached Thermo Fisher Scientific, the world leader in serving science to provide the latest liquid chromatography-mass spectrometry (LC-MS) equipment to enhance their ability to identify and quantify candidate molecules synthesised in drug discovery campaigns.
Two mass spectrometers offer complementary technologies to supply the best and most flexible analytical solution. The Thermo Scientific™ Q Exactive™ Focus Hybrid Quadrupole-Orbitrap™ mass spectrometer offers sensitivity, selectivity, flexibility and ease-of-use. Powered by unique Orbitrap™ technology the system is ideal for screening, quantitation, identification and confirmation of targeted and untargeted compounds allowing XenoGesis to help clients simplify method development and saving time while reliably delivering unsurpassed results.
The second system, the Thermo Scientific™ TSQ Quantiva™ Triple Quadrupole Mass Spectrometer demonstrates superb sensitivity, speed and dynamic range to exceed even the most stringent analytical needs and address the continual trend in research and regulatory requirements driving the need for ever-lower limits of detection and quantitation.
Both mass spectrometers are paired with Thermo Scientific™ Vanquish™ Flex Binary UHPLC systems, a biocompatible, ultra high performance liquid chromatography system which is with a state-of-the-art design focused on uptime, robustness and reliability to allow higher throughput with better separations and easier interaction, all simultaneously and without compromise. A Thermo Scientific™ Vanquish™ Diode Array Detector HL utilises Thermo Scientific™ LightPipe™ technology to provide a second, high-sensitivity detection system.
Thermo Fisher Scientific’s, Life Science Mass Spectrometry, Senior Sales Manager, Sarah Horsley, said “XenoGesis is the UK’s largest independent laboratory-based CRO specialising in preclinical DMPK and bioanalysis and we are very proud to provide XenoGesis with complete workflow solutions for PK, Bioanalysis & Metabolite Identification. This significant investment in state of the art equipment from Thermo Fisher Scientific takes XenoGesis analytical capabilities to the next level, addressing both current and future demands and further strengthening its growing business.”
Director of Bioanalysis and Metabolite Identification at XenoGesis, Iain Beattie, said “The Orbitrap™ adds significantly to the capabilities that XenoGesis can offer by providing accurate mass capability, invaluable for metabolite identification. The Orbitrap’s high resolution capability allows an alternative approach for bioanalysis whilst enhancing our analysis of large molecules including proteins or antibodies. The TSQ Quantiva provides us with a robust, highly sensitive state of the art triple quadrupole mass spectrometer along with the Vanquish UHPLC system maximising sensitivity and throughput. The acquisition of these instruments allows us to expand our bioanalysis as demand increases. We look forward to working with Thermo Scientific to develop enhanced workflow solutions that will ultimately benefit our clients by offering a broader range of capabilities.”
To find out more about XeneGesis, please go to the website.
